DOCSLIB.ORG

Bsc Chemistry

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bsc Chemistry SUBJECT FORENSIC SCIENCE Paper No. and Title PAPER No. 9: Drugs of Abuse MODULE No. 12: Common Stimulants: Amphetamines and Module No. and Title Methamphetamines Module Tag FSC_P9_M12 FORENSIC SCIENCE PAPER No. 9: Drugs of Abuse MODULE No.12: Common Stimulants: Amphetamines and Methamphetamines TABLE OF CONTENTS 1. Learning Outcomes 2. Introduction to Amphetamine 3. Synthesis of Amphetamine and Methamphetamine 4. Use of Amphetamine 5. Fatal Dose 6. Mode of action 7. Signs and Symptoms 8. Withdrawal Symptoms 9. Screening Test 10. Qualitative Analysis 11. Metabolism 12. Designer Amphetamines 13. Medico-legal Aspect 14. Summary FORENSIC SCIENCE PAPER No. 9: Drugs of Abuse MODULE No.12: Common Stimulants: Amphetamines and Methamphetamines 1. Learning Outcomes After studying this module, you will be able to know about- Amphetamines and Methamphetamines Mechanism of Action Amphetamines and Methamphetamines Designer Amphetamines Metabolism of Amphetamines 2. Introduction to Amphetamine Amphetamine (Amfetamine) belongs to the phenylethylamine family with a methyl group substitution in the alpha carbon position. Several substitutions of the phenylethylamine structure are possible, resulting in several amphetamine-like compounds. These compounds collectively known as “amphetamines”, and include Amphetamine Phosphate, Amphetamine Sulphate, Benzphetamine, Chlorphentermine, Clobenzorex Hydrochloride, Dextroamphetamine, Diethylpropion, Mazindol, Methamphetamine, 4-Methylthioamphetamine, Methylphenidate, Pemoline, Phendimetrazine, Phenmetrazine, and Phentermine. Amphetamine was first marketed in the 1930s as “Benzedrine” in over the counter and taken to treat nasal congestion. By 1937 amphetamine was accessible through prescription in tablet form and was used in the treatment of the sleeping disorder Narcolepsy and behavioral syndrome called Minimal Brain Dysfunction (MBD), which nowadays is known as Attention Deficit Hyperactivity Disorder (ADHD). Amphetamine is a stimulant and an appetite suppressant. It excites the Central Nervous System by raising the quantity of various substances in the body. This increase heart rate and blood pressure and reduces craving, besides other effects. Amphetamine, dextroamphetamine and methamphetamine are together denoted as amphetamines. Their chemical properties and action are so alike that even proficient consumers have trouble knowing which drug they have taken. Street names for Amphetamine: Amp, Eye Openers, Road Dope, Sweets, Uppers, Wake Ups, Jelly Bean etc. FORENSIC SCIENCE PAPER No. 9: Drugs of Abuse MODULE No.12: Common Stimulants: Amphetamines and Methamphetamines Derivative of Amphetamines: The derivatives of amphetamines are Methamphetamine, Dextroamphetamine, Fenfluramine, Phentermine, Mephentermine, Methyl phenidate, Synthetic amphetamines („Designer drugs‟) - a. Methylenedioxymeth- amphetamine (MDA or „Love drug‟) b. Methylenedioxyethamphetamine (MDEA or „Ecstasy‟). Amphetamine and methamphetamine are indirect sympathomimetic agents giving rise to release of norepinephrine (noradrenaline) and inhibition of monoamine oxidase. Effects via this action result in hypertension, tachycardia, and inhibition of gut motility. It was this last effect that led to their medical use in treating obesity. However, they are also CNS stimulants and their effect on the CNS soon led to these drugs being abused. Amphetamine (α-methylphenethylamine) and methamphetamine (N-methyl-α- methylphenethylamine) in free-base form are both liquids. Amphetamine is normally produced as amphetamine sulfate, hydrochloride or phosphate and is more commonly abused in Europe than is methamphetamine. Methamphetamine is normally produced as Methamphetamine Hydrochloride and is more popular in North America and Japan than is amphetamine. Street-level amphetamine and methamphetamine are normally submitted to the forensic laboratories as white to off-white powders with relatively low purity (e.g. <20%) but may sometimes occur in tablet form. 3. Synthesis of Amphetamine and Methamphetamine Many methods are available for the licit as well as illicit synthesis of amphetamine, but the Leuckart Reaction has been the most popular. This method is simple, rapid, gives a good yield and does not involve any particularly hazardous chemicals or procedures. It may be considered as a three-step reaction that involves the condensation of Phenyl-2- propanone (P-2-P) with Formamide followed by a hydrolysis of the N- formylamphetamine and finally purification by steam distillation. Methamphetamine can be made by the Leuckart reaction using either Methylamine and Formic Acid or N- methylformamide in the condensation step. FORENSIC SCIENCE PAPER No. 9: Drugs of Abuse MODULE No.12: Common Stimulants: Amphetamines and Methamphetamines Leuckart reaction for the synthesis of amphetamine and methamphetamine Common adulterants for amphetamine include caffeine to increase the stimulant effect and/or to mask low levels of the drug, and sugars (e.g. lactose) used as a diluent. Amphetamine and methamphetamine have isomeric (enantiomeric) forms. Studies have shown that the d-isomer has a more potent effect on the CNS system than the l-isomer and that the d-isomer is eliminated from the body slightly faster than the l-isomer. 4. Use of Amphetamine Some amphetamines have therapeutic uses and are still available as prescription drugs in Western countries but they are not generally available in India (except for Mephentermine). Amphetamine and dextroamphetamine, non-catecholamine sympathomimetic agents, are taken as mixture to treat Attention-Deficit Hyperactivity Disorder (ADHD) or Narcolepsy. They are taken as vasoconstrictors in inhalant therapy to contract nasal mucous membranes in these circumstances as nasal allergies and asthma; now such inhalants have been banned because of their toxicity.4. Action FORENSIC SCIENCE PAPER No. 9: Drugs of Abuse MODULE No.12: Common Stimulants: Amphetamines and Methamphetamines 5. Fatal Dose The fatal dose of amphetamines is highly variable, and whereas death can occur with as diminutive as 1.5 mg/kg of methamphetamine, survival has been recorded with 28 mg/kg. This in fact represents the usual range of amphetamine‟s lethal dose - 150 mg to 2 grams. However, because of tolerance, addicts can tolerate up to 5 grams, or 15 gm/day (smokable methamphetamine). Lethal blood level is said to be around 0.2 mg per 100 ml, though addicts can tolerate much higher levels with hardly any toxic effects. 6. Mode of action The major mechanism of action of amphetamines involves the release of monoamines from storage sites in axon terminals, which leads to increased monoamine concentration in the synaptic cleft. The release of dopamine in the Nucleus Accumbens (NAc) and related structures is responsible for the reinforcing and mood elevating effects of amphetamines. Cardiovascular effects result from the stimulation of release of noradrenaline. The dopamine released into the cytoplasm of neurons undergoes oxidation, resulting in the production of several toxic chemicals (oxygen radicals, peroxides and hydroxyquinones). Amphetamines also have weak Monoamine Oxidase (MAO) inhibiting property, but the significance of this is not clear. The most prominent effects of amphetamines are the catecholamine effects as a result of stimulation of peripheral alpha- and beta-adrenergic receptors. Enhanced concentration of noradrenaline at the locus coeruleus is responsible for the anorexic and stimulating effects, as well as to some extent, for the motor- stimulating effects. The increase in central dopamine (especially in the neostriatum) provokes stereotypical behaviour and some motor effects. The activity of dopamine in the neostriatum appears to be linked to glutamate release and inhibition of GABA-ergic efferent neurons, contributing significantly to the stereotypical behaviour, locomotor effects, and neurotoxicity of amphetamines. The effects of serotonin and dopamine at the mesolimbic system alter perception and induce psychotic manifestations. FORENSIC SCIENCE PAPER No. 9: Drugs of Abuse MODULE No.12: Common Stimulants: Amphetamines and Methamphetamines Amphetamine forms effortlessly absorbed particles that are extremely lipid soluble. The most noticeable monoamine neurotransmitter involved in the effects of the amphetamine is dopamine. Dopamine causes the desirable effects of the drugs, as well as some of the most disturbing psychological effects of the drugs, such as stereotypic behaviors and psychosis. 7. Signs and Symptoms The common signs and symptoms include: Alertness and increased concentration Initial euphoria and more extrovert behaviour Increased talkativeness with rapid speech Increased work capacity with allaying of fatigue Improvement of athletic performance initially followed by further deterioration Stimulation of reticular activating system causing wakefulness and postponement of sleep FORENSIC SCIENCE PAPER No. 9: Drugs of Abuse MODULE No.12: Common Stimulants: Amphetamines and Methamphetamines Hunger is suppressed Tremors Pupils are dilated Tachycardia and hypertension are not so significant High doses produces euphoria, marked excitement, that may progress to mental confusion, delirium, hallucinations and an acute psychotic state Peripheral component of toxicity include vasomotor effects, palpitation, arrhythmias, vomiting, abdominal cramps and vascular collapse Death is uncommon and is usually preceded by convulsions and coma Except that, death due to amphetamine toxicity most commonly results from arrhythmias,
Load more

Recommended publications
  • (Mdma) in Non Conventional Matrices and Its Applications in Clinical Toxicology
    Doctoral Thesis Doctorat Farmacología Departament de Farmacología, de Terapéutica i de Toxicologia DISTRIBUTION OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) IN NON CONVENTIONAL MATRICES AND ITS APPLICATIONS IN CLINICAL TOXICOLOGY SIMONA PICHINI p Doctoral Thesis Doctorat Farmacología Departament de Farmacología, de Terapéutica i de Toxicologia DISTRIBUTION OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) IN NON CONVENTIONAL MATRICES AND ITS APPLICATIONS IN CLINICAL TOXICOLOGY Doctoral thesis submitted by Simona Pichini as a partial fulfillment of the requirements for the degree of Doctor by the Universitat Autònoma de Barcelona. The studies included in this thesis have been realized under the direction of Dr. Rafael de la Torre Fornell and Dr. Magí Farré Albaladejo at the Pharmacology Unit of the Institut Municipal d'Investigació Mèdica (IMIM), Barcelona, Spain; and at the Drug Research and Control Department of the Istituto Superiore di Sanità, Roma, Italy. Doctorate Program of the Universitat Autònoma de Barcelona. Signature of Thesis Director Signature of Thesis Director (Dr. Magí Farré Albaladejo) (Dr. Rafael de la Torre Fornell) Signature of Doctorand (Simona Pichini) Yo soy yo y aquéllos a quienes amo Jorge Bucay To my friends, treasure of my life Acknowledgements Acknowledgements A number of people contributed to high extent to achieve the objectives of this Doctoral Thesis prepared between the two cities of Rome and Barcelona. This means that there are many people I’d the opportunity to meet, to work with, to share wonderful and terrible moments, and that I’d like to thank in these pages. First of all, to Dr. Piergiorgio Zuccaro, my “creator”, who always believed in me, supported my job and hardly fought to give me all the possible opportunities to grow up as an investigator; To Dr.
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Meth/Amphetamine Use and Associated HIV: Implications for Global Policy and Public Health
    International Journal of Drug Policy 21 (2010) 347–358 Contents lists available at ScienceDirect International Journal of Drug Policy journal homepage: www.elsevier.com/locate/drugpo Review Meth/amphetamine use and associated HIV: Implications for global policy and public health Louisa Degenhardt ∗,1, Bradley Mathers 2, Mauro Guarinieri 3, Samiran Panda 4, Benjamin Phillips 5, Steffanie A. Strathdee 6, Mark Tyndall 7, Lucas Wiessing 8, Alex Wodak 9, John Howard 10, the Reference Group to the United Nations on HIV and injecting drug use National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia article info abstract Article history: Amphetamine type stimulants (ATS) have become the focus of increasing attention worldwide. There are Received 29 May 2009 understandable concerns over potential harms including the transmission of HIV. However, there have Received in revised form 30 October 2009 been no previous global reviews of the extent to which these drugs are injected or levels of HIV among Accepted 24 November 2009 users. A comprehensive search of the international peer-reviewed and grey literature was undertaken. Multiple electronic databases were searched and documents and datasets were provided by UN agencies and key experts from around the world in response to requests for information on the epidemiology of use. Keywords: Amphetamine or methamphetamine (meth/amphetamine, M/A) use was documented in 110 countries, Methamphetamine Amphetamine and injection in 60 of those. Use may be more prevalent in East and South East Asia, North America, South HIV Africa, New Zealand, Australia and a number of European countries. In countries where the crystalline Injecting form is available, evidence suggests users are more likely to smoke or inject the drug; in such countries, Epidemiology higher levels of dependence may be occurring.
    [Show full text]
  • 212102Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212102Orig1s000 OTHER REVIEW(S) Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research | Office of Surveillance and Epidemiology (OSE) Epidemiology: ARIA Sufficiency Date: June 29, 2020 Reviewer: Silvia Perez-Vilar, PharmD, PhD Division of Epidemiology I Team Leader: Kira Leishear, PhD, MS Division of Epidemiology I Division Director: CAPT Sukhminder K. Sandhu, PhD, MPH, MS Division of Epidemiology I Subject: ARIA Sufficiency Memo for Fenfluramine-associated Valvular Heart Disease and Pulmonary Arterial Hypertension Drug Name(s): FINTEPLA (Fenfluramine hydrochloride, ZX008) Application Type/Number: NDA 212102 Submission Number: 212102/01 Applicant/sponsor: Zogenix, Inc. OSE RCM #: 2020-953 The original ARIA memo was dated June 23, 2020. This version, dated June 29, 2020, was amended to include “Assess a known serious risk” as FDAAA purpose (per Section 505(o)(3)(B)) to make it consistent with the approved labeling. The PMR development template refers to the original memo, dated June 23, 2020. Page 1 of 13 Reference ID: 46331494640015 EXECUTIVE SUMMARY (place “X” in appropriate boxes) Memo type -Initial -Interim -Final X X Source of safety concern -Peri-approval X X -Post-approval Is ARIA sufficient to help characterize the safety concern? Safety outcome Valvular Pulmonary heart arterial disease hypertension (VHD) (PAH) -Yes -No X X If “No”, please identify the area(s) of concern. -Surveillance or Study Population X X -Exposure -Outcome(s) of Interest X X -Covariate(s) of Interest X X -Surveillance Design/Analytic Tools Page 2 of 13 Reference ID: 46331494640015 1.
    [Show full text]
  • Comparison Between Phenylephrine, Ephedrine and Mephentermine In
    IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 15, Issue 9 Ver. XIII (September. 2016), PP 52-58 www.iosrjournals.org Comparison Between Phenylephrine, Ephedrine And Mephentermine In Preventing Hypotension During Spinal Anesthesia For Caesarean Section And Their Effect On Fetal Outcome. Dr Sarika Sudhir Lonkar1, Dr Sonal Sagar Khatavkar2 Dr W S Thatte3 , Dr Naramaneni Santhi4 Department Of Anesthesia, Dr D Y Patil Medical College, Hospital And Research Centre Pimpri, Pune, Maharashtra, India1,2,3,4. Abstract Aim: To compare of the efficacy and safety of prophylactic bolus doses of intravenous Phenylephrine, Ephedrine, and Mephentermine for maintenance of arterial pressure during spinal anesthesia in caesarean section and their effects on neonate. Settings and Design: The present Prospective Randomized study was carried out in a tertiary care teaching hospital. A total of 90 pregnant women posted for elective caesarean section under spinal anesthesia were enrolled and randomly divided into three groups. Group P (phenylephrine) Group E (ephedrine) Group M (mephentermine) with 30 patients in each group. Materials and Methods: Group E received prophylactic bolus of ephedrine 6 mg IV, group M 6 mg IV mephentermine and group P 100 mcg IV of phenylephrine at the time of subarachnoid block. Hemodynamic variables like blood pressure and heart rate were recorded every 2 minutes up to delivery of baby and then every 5 minutes. Neonatal outcome was assessed using Apgar score at 1 and 5 minutes and neonatal umbilical cord blood pH values. Statistical Analysis Used: Comparitibility of groups are analyzed with analysis variance test to analyzed parametric data ‘P’ value < 0.05 was considered significant.
    [Show full text]
  • Revisão Pharmacological Treatment of Obesity
    Pharmacological Treatment of Obesity revisão ABSTRACT Marcio C. Mancini This review offers an overview of physiological agents, current therapeu- Alfredo Halpern tics, as well as medications, which have been extensively used and those agents not currently available or non-classically considered anti-obesity drugs. As obesity — particularly that of central distribution — represents an important triggering factor for insulin resistance, its pharmacological treatment is relevant in the context of metabolic syndrome control. The authors present an extensive review on the criteria for anti-obesity man- agement efficacy, on physiological mechanisms that regulate central and/or peripheral energy homeostasis (nutrients, monoamines, and pep- tides), on β-phenethylamine pharmacological derivative agents (fenflu- ramine, dexfenfluramine, phentermine and sibutramine), tricyclic deriva- tives (mazindol), phenylpropanolamine derivatives (ephedrin, phenyl- propanolamine), phenylpropanolamine oxytrifluorphenyl derivative (flu- oxetine), a naftilamine derivative (sertraline) and a lipstatine derivative (orlistat). An analysis of all clinical trials — over ten-week long — is also presented for medications used in the management of obesity, as well as data about future medications, such as a the inverse cannabinoid agonist, rimonabant. (Arq Bras Endocrinol Metab 2006;50/2:377-389) Keywords: Obesity; Treatment; Anfepramone; Mazindol; Sibutramine; Endocrinology and Metabology Orlistat; Rimonabant Division, Hospital das Clínicas, University of São Paulo Medical
    [Show full text]
  • Drug-Drug Discrimination: Stimulus Properties of Drugs of Abuse Upon a Serotonergic-Dopaminergic Continuum
    Pharmacology Biochemistry and Behavior, Vol. 56, No. 1, pp. 89±96, 1997 Copyright 1997 Elsevier Science Inc. Printed in the USA. All rights reserved 0091-3057/97 $17.00 1 .00 PII S0091-3057(96)00161-X Drug-Drug Discrimination: Stimulus Properties of Drugs of Abuse Upon a Serotonergic-Dopaminergic Continuum MARTIN D. SCHECHTER Department of Pharmacology, Northeastern Ohio Universities College of Medicine, 4209 S.R. 44, Rootstown, Ohio 44272 USA Received 14 December 1995; Revised 5 March 1996; Accepted 13 March 1996 SCHECHTER, M. D. Drug-drug discrimination: Stimulus properties of drugs of abuse upon a serotonergic-dopaminergic continuum. PHARMACOL BIOCHEM BEHAV 56(1) 89±96, 1997.ÐTen male N/Nih rats were trained to discriminate between the interoceptive cues produced by the purportedly dopaminergically-mediated drug d-amphetamine at 0.4 mg/kg intraperitoneally administered 20 min prior to training and those produced by the purportedly serotonergically-active agent norfen¯uramine at 0.7 mg/kg. Once this discrimination was successfully acquired, the rats were tested with saline and with both drugs administered simultaneously and these manipulations were seen to produce random responding; indicating roughly equivalent cueing strength. Subsequently, various drugs thought to act upon serotonergic neurons, i.e., LSD and MDMA, were tested and shown to generalize in a dose-responsive manner to the norfen¯uramine-appropriate lever. In contrast, the dopaminergically-active agent methcathinone and the D3 agonist 7-OH-DPAT produced generalization on the amphetamine- appropriate lever. Results are discussed in light of the increased speci®city of behavioral testing available in a drug vs.
    [Show full text]
  • Schedules of Controlled Substances (.Pdf)
    PURSUANT TO THE TEXAS CONTROLLED SUBSTANCES ACT, HEALTH AND SAFETY CODE, CHAPTER 481, THESE SCHEDULES SUPERCEDE PREVIOUS SCHEDULES AND CONTAIN THE MOST CURRENT VERSION OF THE SCHEDULES OF ALL CONTROLLED SUBSTANCES FROM THE PREVIOUS SCHEDULES AND MODIFICATIONS. This annual publication of the Texas Schedules of Controlled Substances was signed by John Hellerstedt, M.D., Commissioner of Health, and will take effect 21 days following publication of this notice in the Texas Register. Changes to the schedules are designated by an asterisk (*). Additional information can be obtained by contacting the Department of State Health Services, Drugs and Medical Devices Unit, P.O. Box 149347, Austin, Texas 78714-9347. The telephone number is (512) 834-6755 and the website address is http://www.dshs.texas.gov/dmd. SCHEDULES Nomenclature: Controlled substances listed in these schedules are included by whatever official, common, usual, chemical, or trade name they may be designated. SCHEDULE I Schedule I consists of: -Schedule I opiates The following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, if the existence of these isomers, esters, ethers, and salts are possible within the specific chemical designation: (1) Acetyl-α-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide); (2) Acetylmethadol; (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) (Other name:
    [Show full text]
  • 1 441 702 B1
    (19) TZZ__Z _T (11) EP 1 441 702 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/4045 (2006.01) A61P 25/20 (2006.01) 10.05.2017 Bulletin 2017/19 A61K 9/20 (2006.01) (21) Application number: 02760523.7 (86) International application number: PCT/IL2002/000662 (22) Date of filing: 12.08.2002 (87) International publication number: WO 2003/015690 (27.02.2003 Gazette 2003/09) (54) METHOD FOR TREATING PRIMARY INSOMNIA VERFAHREN ZUR BEHANDLUNG PRIMÄRER INSOMNIA METHODE DE TRAITEMENT DE L’INSOMNIE PRIMAIRE (84) Designated Contracting States: • ROTH T ET AL: "Consensus for the AT BE BG CH CY CZ DE DK EE ES FI FR GB GR pharmacological management of insomnia in th IE IT LI LU MC NL PT SE SK TR enew millennium", INTERNATIONAL JOURNAL Designated Extension States: OF CLINICAL PRACTICE, MEDICON LT LV RO SI INTERNATIONAL, ESHER, GB, vol. 55, no. 1, 1 January 2001 (2001-01-01), page 10PAGES, (30) Priority: 14.08.2001 IL 14490001 XP002990688, ISSN: 1368-5031 • PERLIS M L ET AL: "Psychophysiological (43) Date of publication of application: insomnia: the behavioural model and a 04.08.2004 Bulletin 2004/32 neurocognitive perspective", JOURNAL OF SLEEP RESEARCH, BLACKWELL SCIENTIFIC, (60) Divisional application: OXFORD, GB, vol. 6, 1 January 1997 (1997-01-01), 16172415.8 / 3 103 443 pages 179-188, XP002990686, ISSN: 0962-1105, DOI: DOI:10.1046/J.1365-2869.1997.00045.X (73) Proprietor: NEURIM PHARMACEUTICALS (1991) • SILVA J A C E ET AL: "Special report from a LIMITED symposium held by the WHO and the World Tel Aviv 69710 (IL) Federation of sleep research societies: an overview of insomnias and related disorders - (72) Inventor: ZISAPEL, Nava recognition, epidemiology and rational 69355 Tel Aviv (IL) management", SLEEP, ALLEN PRESS, LAWRENCE, KS,US, vol.
    [Show full text]
  • Appetite Suppressants and Pulmonary Hypertension
    Thorax 1997;52(Suppl 3):S63±S67 S63 Thorax: first published as 10.1136/thx.52.2008.S63 on 1 August 1997. Downloaded from Appetite suppressants and pulmonary hypertension N F Voelkel Pulmonary Hypertension Center, University of Colorado Health Sciences Center, Denver, Colorado, USA Introductory article Appetite-suppressant drugs and the risk of primary pulmonary hypertension L Abenhaim, Y Moride, F Brenot, S Rich, J Binichou, X Kurz, T Higenbottam, C Oakley, E Wouters, M Aubier, G Simonneau, B Begaud for the International Primary Pulmonary Hypertension Study Group Background. Recently in France, primary pulmonary hypertension developed in a cluster of patients exposed to derivatives of fen¯uramine in appetite suppressants (anorexic agents), which are used for weight control. We investigated the potential role of anorexic agents and other suspected risk factors for primary pulmonary hypertension. Methods. In a case-control study, we assessed 95 patients with primary pulmonary hypertension from 35 centers in France, Belgium, the United Kingdom, and the Netherlands and 355 controls recruited from general practices and matched to the patients' sex and age. Results. The use of anorexic drugs (mainly derivatives of fen¯uramine) was associated with an increased risk of primary pulmonary hypertension (odds ratio with any anorexic-drug use, 6.3; 95 percent con®dence interval, 3.0 to 13.2). For the use of anorexic agents in the preceding year, the odds http://thorax.bmj.com/ ratio was 10.1 (95 percent con®dence interval, 3.4 to 29.9). When anorexic drugs were used for a total of more than three months, the odds ratio was 23.1 (95 percent con®dence interval, 6.9 to 77.7).
    [Show full text]
  • Chapter 961 Uniform Controlled Substances Act
    1 Updated 01−02 Wis. Stats. Database UNIFORM CONTROLLED SUBSTANCES ACT 961.01 CHAPTER 961 UNIFORM CONTROLLED SUBSTANCES ACT 961.001 Declaration of intent. 961.437 Possession and disposal of waste from manufacture of methamphetamine. SUBCHAPTER I 961.438 Minimum sentence. DEFINITIONS 961.44 Penalties under other laws. 961.01 Definitions. 961.45 Bar to prosecution. SUBCHAPTER II 961.455 Using a child for illegal drug distribution or manufacturing purposes. 961.46 Distribution to persons under age 18. STANDARDS AND SCHEDULES 961.465 Distribution to prisoners. 961.11 Authority to control. 961.47 Conditional discharge for possession or attempted possession as first of- 961.115 Native American Church exemption. fense. 961.12 Nomenclature. 961.472 Assessment; certain possession or attempted possession offenses. 961.13 Schedule I tests. 961.475 Treatment option. 961.14 Schedule I. 961.48 Second or subsequent offenses. 961.15 Schedule II tests. 961.49 Distribution of or possession with intent to deliver a controlled substance 961.16 Schedule II. on or near certain places. 961.17 Schedule III tests. 961.492 Distribution or possession with intent to deliver certain controlled sub- 961.18 Schedule III. stances on public transit vehicles. 961.19 Schedule IV tests. 961.495 Possession or attempted possession of a controlled substance on or near 961.20 Schedule IV. certain places. 961.21 Schedule V tests. 961.50 Suspension or revocation of operating privilege. 961.22 Schedule V. SUBCHAPTER V 961.23 Dispensing of schedule V substances. ENFORCEMENT AND ADMINISTRATIVE PROVISIONS 961.24 Publishing of updated schedules. 961.51 Powers of enforcement personnel.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]